Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate the efficacy and safety of an insulin-sensitizer
(Actos) added to a standard Pegasys/Copegus combination therapy of chronic hepatitis C in
patients who have previously failed a pegylated-interferon-alpha / ribavirin combination
without the insulin sensitizer. The primary endpoint is the initial virological response
(level of HCV RNA in serum) as evaluated after 12 weeks of triple therapy.